IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
暂无分享,去创建一个
A. Salar | A. Guillermo | M. Merli | E. Zucca | C. Visco | M. Raderer | M. Pirosa | A. Tucci | D. Mannina | B. Kiesewetter | F. Esposito | M. Sassone | L. Devizzi | L. Bonomini | A. Ferreri | E. D. Domènech
[1] R. Marcus,et al. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma , 2021, Clinical Cancer Research.
[2] J. Burke,et al. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Santoro,et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. , 2021, Blood advances.
[4] C. Flowers,et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. , 2020, Blood advances.
[5] M. Raderer,et al. Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B‐cell lymphoma of the mucosa associated lymphoid tissue (MALT‐lymphoma) outside of clinical trials: Real‐world data from the University of Vienna , 2020, Hematological oncology.
[6] A. Salar,et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Gribben,et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] I. Flinn,et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Calimeri,et al. Clarithromycin as a “repurposing drug” against MALT lymphoma , 2018, British journal of haematology.
[10] F. Cavalli,et al. A MALT lymphoma prognostic index. , 2017, Blood.
[11] Hua Zhang,et al. Minimax and admissible adaptive two-stage designs in phase II clinical trials , 2016, BMC Medical Research Methodology.
[12] C. Huff,et al. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma , 2014, American journal of hematology.
[13] W. Dolak,et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.
[14] C. Copie-Bergman,et al. Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice , 2013, British journal of haematology.
[15] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.